CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
As 2025 comes to a close, the editors at The Scientist asked researchers to reflect on the biggest breakthroughs in cell biology this year. They named advances in everything from embryo models for ...
Three weeks ago, on January 5, Graphite Bio announced a voluntary pause of their Phase I/II CEDAR clinical trial of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) after observing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback